The Rosalind and Morris Goodman Cancer Research Centre

Annual Report

January – December 2012
# Rosalind and Morris Goodman Cancer Centre Annual Report 2012

## Table of Contents

### Section I: Unit Status Update

Highlights of achievements and activities for the year 2012  page 4

### Section II: Supporting documentation

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>List of academic staff</td>
<td>10</td>
</tr>
<tr>
<td>II</td>
<td>Grants</td>
<td>11</td>
</tr>
<tr>
<td>III</td>
<td>Salary support</td>
<td>26</td>
</tr>
<tr>
<td>IV</td>
<td>Publications</td>
<td>27</td>
</tr>
<tr>
<td>V</td>
<td>Community involvement</td>
<td>43</td>
</tr>
</tbody>
</table>

### Section III: Confidential Information

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>VI</td>
<td>Consulting Activities Table</td>
<td>61</td>
</tr>
</tbody>
</table>
Section I
Unit Status Update
I. Introduction
The Rosalind and Morris Goodman Cancer Research Centre (GCRC) is recognized as one of the leading cancer research centers in Canada and abroad. Its thematic division into 5 units: Breast Cancer, Metabolism and Cancer, Development and Cancer, Stem Cells and Signaling, and DNA and Apoptosis, has resulted in creating a critical mass of specialists who are accelerating discoveries in these fields of research, initiating meaningful partnerships with clinical and basic scientists at a national and international level, and are very effective at securing personal and team grants with external funding agencies. Most importantly, the emphasis is on fundamental, translational and clinical aspects of cancer research, maintenance of the cutting-edge, state-of-the art facilities and enriched, multidisciplinary, and collaborative training environment. As such, the Centre attracts many gifted trainees, research staff, and scientific interest. Despite budgetary limits and national economic constrains the Centre continues to deliver more with less due to its lean policy and close administrative oversight.

The mission of the Goodman Cancer Research Centre has remained the same since its establishment in 1978. The three major elements are as follows:
1) To bring together internationally renowned scientists devoted to cancer research and provide them with the best resources available so that they are poised to fully contribute to the worldwide effort to cure cancer.
2) To provide an internationally recognized state-of-the-art training platform for the next generation of researchers.
3) To promote to the public and to the medical community the importance of fundamental research for the advancement of cancer understanding, prevention, prognosis and treatment.

In 2012, the GCRC had 25 full members, 31 associate members, 57 MSc students, 68 Ph.D. students, 52 postdoctoral fellows, and 14 summer students.

The 2012 achievements and activities are summarized below.

II. Research and Publications
The overall research activities in the Centre are supported by the grants secured and held by the full members of GCRC (Full list of GCRC members: Appendix I). Specifically, in 2012 the total amount of grants held by GCRC and their full members (Grants: Appendix II) amounted to $ 17 million:

- Infrastructure Grants: $900,000
- Team Grants (6 grants): $4,084,170 (24% of total grants held)
- Individual Grants (25 full members; total of 134 grants held): $11,954,801
  - Individual grants secured in 2012 (17 full members; 35 grants): $1,706,687 (10% of total grants held)

GCRC continued to hold the prestigious Fonds de recherche du Québec – Santé (FRQS) research group status in 2012 with a direct funding of $425,000 per year. This funding is in place until year 2015. In addition, financial support from CFI-IOF in the amount $150,000 was available in support of the newly established Metabolomics Facility (CFI-VI 2009; 2010-2016 total funding period).

The Centre continues to offer a very much sought-after research training environment and manages the McGill Integrated Cancer Research Training Program for which a competitive grant was secured from CIHR/FRQS in the amount of $325,000 per year (2009-2015 total funding period). Thanks to this initiative, close to 30 trainees per year receive partial salary support while pursuing cancer research at not
only GCRC but also at the Segal Cancer Centre and MUHC RI. Similarly, 20 trainees per year benefit from travel support to present their research at national and international scientific meetings.

Research at the Centre continues to be supported by the funding received via 6 Team grants secured by the GCRC researchers, where 2 of the grants were obtained in 2009 (CIHR, CCSRI), 2 in 2010 (GQ, QCDM) and 2 in 2011 (CIHR, GQ). The importance of these team grants lies in the fact that 1) it reflects the strength of the collaborative spirit of the members of the Centre, and 2) portion of the funds are dedicated towards the research and operations of key facilities established at GCRC (Metabolomics Facility, Laboratory for Therapeutic Development, Histology, Transgenic and Functional Genomics Core Facilities).

Individual funding obtained by the full members of the GCRC, is due to the innovative work of our colleagues and the existence of outstanding infrastructure. In 2012, all of our full members held grants (135) in the amount of $11,954,801 to support their research activities, trainees and personnel. Of those, $1,706,687 was secured in the form of operating grants by 17 researchers in 2012 (35 grants). Additionally, 16 of GCRC members held salary support from the prestigious career awards totaling over $ 1 million (Detailed list: Appendix III). We are happy to report that our newest member, Dr. George Zogopoulos who joined the GCRC as a full member in 2011, successfully secured salary support in 2012.

In addition, and among other GCRC exceptional outputs, GCRC PIs have filed several patents and licensing agreements.


Researchers continue to publish actively and in 2012 they collectively published over 137 peer reviewed manuscripts and book chapters, a 33% increase over the previous reporting period. Many of these were published in the leading scientific journals in the world: Nature, Nature Immunology, Nature Communications, Cancer Cell, Molecular Cell, Cell Metabolism, Oncogene, Cancer Research, Molecular Cell Biology, Journal of Immunology, Development, and PNAS among others (Detailed list of publications: Appendix IV).

III. Conferences and Symposia

Each year the GCRC members are involved in the organization of the national and international scientific conferences and/or symposia.

- Dr. Philip Branton and Dr. Jose Teodoro organized the 2012 DNA Tumour Virus meeting for the first time in Montreal (July 16 – 21, 2012). This meeting brings together a diverse group of researchers, from all over the world, with common research interests in the study of the small DNA tumor viruses. It is the first time since 1969 that this meeting was held in Montreal.
- Dr. Nicole Beauchemin was part of the organization committee for the Signalisation-Quebec meeting in Trois-Rivières in 2012. This meeting brings together all researchers in Quebec using Molecular Signaling as readout of their phenotypic experiments.
- Dr. Russell Jones was a co-organizer of the FASEB Summer Research Conference entitled “AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities” and held in Asilomar, CA, USA (October 7-12, 2012).
- Dr. Arnim Pause was the member of the scientific committee, session chair, and invited speaker at the...

- Dr. Nahum Soneneberg was the co-organizer with D. Tollervey, J. Steitz and A. Ephrussi of the EMBO/EMBL Symposium 2012 “Complex Life of mRNA” in Heidelberg, Germany (October 7-10, 2012).

Many of GCRC members travel extensively as invited speakers/research experts to present at national/international meetings or at the departmental seminars and workshops. Among more prestigious presentations in 2012 were:

- Dr. N. Beauchemin gave a Keynote address at the 40th annual meeting of International Society for Oncology and Biomarkers (ISOBM), Jerusalem, Israel (October 13-17, 2012).
- Dr. N. Sonenberg gave a keynote address at the workshop entitled “mRNA FATE: Life and Death of mRNA in the Cytoplasm” organized by the RNA Society in Riva del Garda, Italy (May 23-26, 2012).

IV. Teaching and learning

The Centre continues to provide a rich and stimulating training environment. In 2012 all of our scientists taught in various undergraduate/graduate level courses, served as course coordinators or on academic advisory boards, supervised and mentored graduate and postdoctoral trainees. Few highlights include:

*Teaching Excellence Award:* Dr. Russell Jones received the “Dr. Ann Wechsler Award for Excellence in the Teaching of Physiology” in 2012 (also recipient in 2011 and 2013).

*Teaching initiatives:* The Experimental and Clinical Oncology Course EXMD 635 continues to be administered and managed by GCRC. It is a year-long, trans-disciplinary course with lectures on the latest and most relevant cancer disciplines delivered by 40 basic and clinical researchers, who are experts in their respective fields. Lectures on different types of cancer are given by a team of 2 professors (basic scientist paired with a clinician) such that students learn how the basic research knowledge makes its way into clinical practice and decision-making. Tumor Board meetings are offered as part of the course must be attended by all students. This activity puts in perspective the lessons learned at the bench and their impact on clinical decision-making process in cancer treatment. The course is very popular and the registration for the 2012-2013 academic year was at its record high of 51 students. In 2012, Dr. Nicole Beauchemin submitted a proposal for initiation of substantial course review which commenced in the Fall of 2012.

We are also very proud of our trainees who continue to apply and receive competitive funding support. In 2012, graduate students and postdoctoral fellows received stipend awards for a combined total of $373,000 by means of internal funding competitions.

- Canderel Awards: *Graduate students:* Ch. Cyr-Depauw, Y. Stern, Z. Andrei; *Postdoctoral fellows:* M. Poffenberger, E Matta Camacho

In addition, numerous GCRC trainees (M.Sc. and Ph.D. students as well as PDFs) also secured funding from external sources, including provincial, federal and international funding agencies (FRQS, CRS, CIHR, Susan Komen, US Army – DOD, and many others). Combined with the internal studentships, GCRC trainees secured just over 1.6 million dollars competitive awards.
V. Involvement in the community
The GCRC and its members highly value the involvement in the community. For this reason, the Goodman Public Forum lecture series have been developed with a specific goal of broadcasting scientific discoveries and knowledge to the general public. These events are moderated by Dr. Nicole Beauchemin and are very popular and very well attended (200 participants). In 2012, GCRC have delivered 4 such events:

- **October 15, 2012:** Bladder and prostate cancer (Invited panelists: Drs. Fred Saad, Michel Tremblay, Wassim Kassouf and cancer survivor).
- **November 12, 2012:** cancer looking for simplicity and finding complexity (Invited Panelists: Drs. Walter Gotlieb, Anne-Marie Mes-Masson, John Stagg).
- **March 13, 2012:** Lung Cancer: Myths, facts, choices (Invited Panelists: Drs. Simon Rousseau, Jason Agulnik, Bassam Abdulkarim).
- **April 24, 2012:** Melanoma: making a mountain out of a mole? (Facilitator: Dr. Nicole Beauchemin; Invited Panelists: Drs Henry Shibata, Beatrice Wang, Francine Tremblay, David Dankort).

In addition, each member of the GCRC dedicates a lot of their time to sit on the scientific and academic committees, to actively participate in the grant, journal and advisory review panels and editorial boards, and is often invited to be part of the McGill’s internal committees (please see Appendix V for details).

VI. Milestones:
Dr. Morag Park has accepted the position of the GCRC Director in the fall of 2012 and will commence her official mandate on July 1st, 2013.

Promotions:

**Associate Professorship:**
- Dr. T. Duchaine became the Associate Professor in Department of Biochemistry at McGill University on June 2012.

**Associate Members:**
- Dr. G. Zogopoulos an Associate Member of the Department of Human Genetics and Medicine (Division Experimental Medicine) at McGill University in 2012.
- Dr. J. Teodoro became the Associate Member of the Department of Microbiology and Immunology at McGill University in April 2012.
- Dr. Lorenzo Ferri, an Assistant Professor in the Departments of Surgery has become GCRC newest member in 2012. His research focus is on 1) the role of systemic inflammation in cancer metastasis, 2) signaling in cancer cells, and 3) neutrophil role in cancer progression.

Retirement:
Dr. Maria Zannis-Hadjopoulos indicated her desire to retire as of June 2013.

Administration:
- Mr Jacques Hendlisz completed his mandate of reorganizing the GCRC administrative infrastructure and left GCRC in December 2012.
- Ms Petra Gaiser was hired as the administrative officer at GCRC starting January 2013. Her mandate includes optimization of the administrative and research operations.
New faculty positions:
GCRC has initiated a search to fill two new faculty positions in the area of lung cancer. The first is the Goodman endowed chair in lung cancer, which is targeting an established clinician/scientist that will bridge clinical and basic research in the field of lung cancer. The second is an Assistant Professor position for a basic research scientist interested in the molecular mechanisms driving lung cancer initiation and progression. These searches are currently ongoing with the anticipated recruitment to these positions concluding in 2013/2014.

VII. Honors, awards, and prizes:
Some of our faculty members received prestigious recognitions:
- Dr. N. Beauchemin was nominated by the Dept. of Oncology and the Goodman Cancer Research Centre for the Royal Society of Canada. Dossier will go forward next year.
- Dr. T. Duchaine became the Riboclub Alumni of the Year (Distinction with honorary lecture)
- Dr. Jerry Pelletier was awarded James McGill Professor, McGill University (2012-2019)
- Dr. N. Sonenebrg received the Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Science
- Dr. M. Tremblay received the Prix Michel Sarrazin 2012 from Club de Recherche Clinique du Quebec
- Dr. G. Zogopoulos became the Alternate Appointee for the Franklin Martin Faculty Research Fellowship, American College of Surgeons

Finally, some of GCRC members take part in consulting activities (Consulting Activities Table: Appendix VI).

We are incredibly proud of the achievements of our faculty, trainees and staff of the Goodman Cancer Research Centre. Our researchers remain highly competitive in both the excellence of their research programs and their ability to secure funding, at all levels, in an increasingly competitive funding environment. As we look forward to 2013, we welcome Dr. Morag Park as the 7th Director of the Goodman Cancer Research Centre. The arrival of Dr. Park will provide the opportunity for the GCRC to define its strategic priorities moving forward at a time when similar initiatives are being pursued at the Faculty and University levels. We also look forward to launching the recruitment process to develop a critical mass in lung cancer research that will add to and grow our strength in this area. As Universities across Canada struggle with current fiscal realities, we are fortunate that the GCRC can continue to develop new areas of research strength that complement our existing research excellence. Finally, we are fortunate that we enjoy the unwavering support of Rosalind and Morris Goodman, which allows the Centre to strategically develop in these challenging times.

Sincerely,

Peter Siegel, Interim Director
Section II
Supporting documentation
APPENDIX I

Unit Status Update

BEAUCHEMIN, Nicole, Professor (on leave Jan - Dec 2012)
BOUCHARD, Maxime, Associate Professor (active)
BRANTON, Philip, Professor (active)
DUCHAINE, Thomas, Associate Professor (active)
GALLOUZI, Imed, Associate Professor (active)
GIGUERE, Vincent, Professor (active)
GROS, Philippe, Professor (active)
HALLETT, Michael, Associate Professor (active)
JONES, Russell, Assistant Professor (active)
McCAFFREY, Luke, Assistant Professor (active)
MULLER, William, Professor (active)
NEPVEU, Alain, Professor (active)
PARK, Morag, Professor (active)
PAUSE, Arnim, Associate Professor (active)
PELLETIER, Jerry, Professor (active)
SHORE, Gordon, Professor (active)
SIEGEL, Peter, Associate Professor, Interim Director at GCRC (active)
SONENBERG, Nahum, Professor (active)
ST-PIERRE, Julie, Assistant Professor (active)
TEODORO, Jose, Assistant Professor (active)
TREMBLAY, Michel, Professor (on leave till October 2012)
YAMANAKA, Yojiro, Assistant Professor (active)
YANG, Xiang-Jiao, Professor (active)
ZANNIS-HADJOPOULOS, Maria, Professor (on leave till June 2012)
ZOGOPOULOS, George, Assistant Professor of Surgery (active)
APPENDIX II
Research Grants Obtained
(January-December 2012)

Notes:
Infrastructure Grants – from $851,250 (2011) to $900,000 (2012)

Please note that GCRC secured funds for this reporting period are:
- $900,000 secured from granting agencies for GCRC personnel, training activities (trainees salary support) and establishing and maintaining of Metabolomics Facility
- $4,084,170 secured for team driven research programs
- $11,954,801 secured by GCRC full members for their research projects

Dollar amounts indicated are for the actual number of funded months in 2012. i.e. If the funding period spans across only 3 months in 2012, the amount indicated represents 3 months of funding.

For group grants on which the PI is part of the Goodman Cancer Research Centre (GCRC), the full amount of funding for 2012 (12 months) has been attributed to the PI for reporting purposes. For group grants on which the PI is not from the GCRC, the individual researcher's share for the 12-month period is indicated.

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Team Leader</th>
<th>Title</th>
<th>Funding Period</th>
<th>Jan-Dec 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRSQ</td>
<td>Infrastructure</td>
<td></td>
<td>Groupe de recherche sur le cancer de McGill</td>
<td>04/2011-03/2015</td>
<td>$425,000</td>
</tr>
<tr>
<td>CIHR/FRSQ</td>
<td>Strategic Training Initiative</td>
<td>Michel Tremblay</td>
<td>The CIHR/FRSQ Training Program in Cancer Research at McGill (Training grant of the GCRC, Segal Cancer Centre and MUHC) (MICTRP) CoPI: Wilson Miller CoApps: Beauchemin, Bouchard, Duchaine, Giguere</td>
<td>04/2011-03/2015</td>
<td>$325,000</td>
</tr>
</tbody>
</table>
## Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>IOF-CFI_6</th>
<th>Institutional Operating Fund</th>
<th>Vincent Giguere</th>
<th>Metabolism and Cancer: From Obesity to Cachexia</th>
<th>06/2010-06/2016</th>
<th>$150,000</th>
</tr>
</thead>
</table>

### GCRC Group Grants (total $4,084,170)

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Team Leader</th>
<th>Title</th>
<th>Funding Period</th>
<th>May2011-Apr2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>STIHR</td>
<td>Michael Hallett</td>
<td>Integrative Approaches to Human Health <strong>CoApps:</strong> Gros, Muller, Park, Pelletier, Siegel + 46 others (GCRC, McGill and MUHC)</td>
<td>04/2009-03/2015</td>
<td>$298,333</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>Michel Tremblay</td>
<td>Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities. <strong>CoPIs:</strong> Jones, Pause, Sonenberg, St-Pierre <strong>CoApps:</strong> Avizonis, Beauchemin, Giguere, Hardy, Nadon, Pollak, Topisirovic</td>
<td>07/2011-06/2014</td>
<td>$1,277,101</td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNFPPG</td>
<td>William Muller</td>
<td>Preclinical models and therapeutic targets for metastatic breast disease <strong>CoApps:</strong> Giguere, Hallett, Muller, Park, Siegel</td>
<td>07/2009-06/2014</td>
<td>$1,030,684</td>
</tr>
<tr>
<td>GQ</td>
<td>Genomics Research in Human Health</td>
<td>Michael Hallett</td>
<td>Next Generation Predictive Signatures for Breast Cancer <strong>CoApps:</strong> Avard (McGill, Human Genetics), Gaboury (IRIC), Muller, Nepveu, Park, Siegel, Ursini-Siegel (LDI/JGH)</td>
<td>01/2011-12/2013</td>
<td>$483,186</td>
</tr>
<tr>
<td>GQ</td>
<td>Concours santé-volet translationel</td>
<td>Gordon Shore</td>
<td>Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer <strong>CoPI:</strong> Michel Tremblay <strong>CoApps:</strong> Giguere, Jones, Pelletier, St-Pierre and J. Lachaine (U de M)</td>
<td>10/2010-09/2013</td>
<td>$324,869</td>
</tr>
<tr>
<td>CQDM</td>
<td>Operating</td>
<td>Gordon Shore</td>
<td>Integrated Platform: Synthetic Lethality in Cancer <strong>CoApps:</strong> Muller, Pelletier, Sonenberg, Tremblay</td>
<td>09/2010-08/2013</td>
<td>$669,997</td>
</tr>
</tbody>
</table>
### GCRC Individual Grants (total $11,954,801)

#### BEAUCHEMIN, Nicole

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Metabolic functions of the PTPase SHP-1 in insulin target tissues</td>
<td>04/2012-03/2017</td>
<td>$18,750</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>CEACAM1 in colon cancer progression and metastasis</td>
<td>04/2012-03/2017</td>
<td>$125,115</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Innovation</td>
<td></td>
<td>Host genetic determinants of colon cancer metastasis</td>
<td>01/2012-12/2014</td>
<td>$8,333</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td>Co-PI wGros</td>
<td>Genetic control of susceptibility to colon cancer development</td>
<td>09/2012-08/2014</td>
<td>$10,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Metabolic control pathways in cancer: Control of the Warburg effect by AMPK CoPIs: Jones, Pause, Sonenberg, St-Pierre CoApps: Avizonis, Beauchemin, Giguere, Hardy, Nadon, Pollak, Topisirovic</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CQDM</td>
<td>CQDM</td>
<td></td>
<td>SN-38 (or 5-FU) drug encapsulation in liposomes transported by magnetotactic bacteria for localized colorectal cancer treatment</td>
<td>09/2011-08/2014</td>
<td>$11,000</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td>Co-PI wGros</td>
<td>Genetic Control of Susceptibility to Colon Cancer</td>
<td>09/2010-08/2012</td>
<td>$20,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>CEACAM1 in colon cancer progression</td>
<td>04/2008-03/2012</td>
<td>$46,126</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Metabolic functions of the PTPase SHP-1 in insulin target tissues</td>
<td>04/2007-03/2012</td>
<td>$4,250</td>
</tr>
</tbody>
</table>

#### BOUCHARD, Maxime

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>KFoC</td>
<td>Biomedical</td>
<td></td>
<td>Mouse models of urogenital developmental diseases</td>
<td>07/2012-06/2014</td>
<td>$25,000</td>
</tr>
<tr>
<td>McGill U.</td>
<td>Bridge Funding</td>
<td></td>
<td>Specification and Morphogenesis of the Urogenital System Primordium</td>
<td>10/2012-09/2013</td>
<td>$8,750</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Gata3 and the Androgen Receptor Response in Prostate Cancer</td>
<td>09/2011-08/2013</td>
<td>$60,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Transcriptional network of urogenital system development in the mouse</td>
<td>09/2007-08/2012</td>
<td>$86,904</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>LAR-family receptor tyrosine phosphatases in urogenital system malformations</td>
<td>09/2007-08/2012</td>
<td>$83,199</td>
</tr>
<tr>
<td>KFC</td>
<td>Biomedical Research Grant</td>
<td>Mouse models of urogenital system developmental diseases</td>
<td>07/2010-06/2012</td>
<td>$25,000</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
</tbody>
</table>

**BRANTON, Philip**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Role of the E4orf6/E1B55K E3 ubiquitin ligase in the adenovirus life cycle</td>
<td>04/2010-03/2015</td>
<td>$221,455</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Mechanism of action of the adenovirus death protein E4orf4 (total $145,894/yr less Teodoro’s $20,000/yr)</td>
<td>04/2009-03/2014</td>
<td>$125,894</td>
</tr>
<tr>
<td>CIHR</td>
<td>Dissemination Events</td>
<td></td>
<td>Montreal DNA Tumour Virus Meeting 2012</td>
<td>2012</td>
<td>$16,756</td>
</tr>
</tbody>
</table>

**DUCHAINE, Thomas**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Synergistic miRNA-binding sites, and 3’ untranslated regions: a dialogue of silence</td>
<td>10/2012-09/2017</td>
<td>$33,170</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery Grants</td>
<td></td>
<td>Making sense of antisense: the activities of RNA-dependent RNA polymerases in endogenous RNAi</td>
<td>04/2012-03/2017</td>
<td>$21,127</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td>wSonenberg</td>
<td>Mechanism of microRNA action in translation and mRNA decay</td>
<td>04/2009-03/2014</td>
<td>$125,323</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>RNAi-mediated Genetic Regulation Loops</td>
<td>03/2008-03/2013</td>
<td>$125,323</td>
</tr>
<tr>
<td>CFI</td>
<td>Leaders Opportunity Fund</td>
<td></td>
<td>An integrative approach on small RNA-mediated silencing in Canada</td>
<td>09/2007-09/2012</td>
<td>$60,644</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>The role of tandem tudor domain proteins in RNAi</td>
<td>04/2007-03/2012</td>
<td>$7,043</td>
</tr>
</tbody>
</table>

**GALLOUZI, Imed**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The role of trans- and cis-acting factors in the regulation of mRNA encoding modulators of senescence and SASPs</td>
<td>04/2012-03/2017</td>
<td>$120,591</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The RNA binding protein HuR is a key player in muscle cell differentiation</td>
<td>09/2008-09/2013</td>
<td>$135,184</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>Identification of the posttranscriptional regulatory network of the pro-inflammatory cytokine HMGB1</td>
<td>07/2009-06/2014</td>
<td>$56,000</td>
</tr>
</tbody>
</table>
The RNA binding protein HuR is a key player in cancer induced muscle wasting

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCIC</td>
<td>Operating</td>
<td></td>
<td>The RNA binding protein HuR is a key player in cancer induced muscle wasting</td>
<td>07/2007-06/2012</td>
<td>$64,000</td>
</tr>
</tbody>
</table>

### GIGUERE, Vincent

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Molecular and genetic analysis of ERR function in breast cancer</td>
<td>10/2011-09/2016</td>
<td>$165,216</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Transcriptional control of metabolism by estrogen related receptors (ERRs)</td>
<td>04/2011-03/2016</td>
<td>$172,628</td>
</tr>
<tr>
<td>GQ</td>
<td>Large-scale project</td>
<td>wShore</td>
<td>Therapeutic development platform: targeting metabolism in cancer therapy</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Defining and Applying Oncometabolism</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNFPPG</td>
<td>wMuller</td>
<td>Preclinical models and therapeutic targets for metastatic breast disease</td>
<td>07/2009-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>Omega-Chem Inc.</td>
<td>Research Contract</td>
<td></td>
<td>Biological Testing of DIAT-Steroids on a series of Nuclear Receptors</td>
<td>02/2012-06/2012</td>
<td>$15,193</td>
</tr>
<tr>
<td>GQ</td>
<td>Pilot Project</td>
<td>wSt-Pierre</td>
<td>Metabolomics of ErbB2-induced breast tumors</td>
<td>10/2010-09/2012</td>
<td></td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Genetic and functional analyses of orphan nuclear receptor functions</td>
<td>10/2007-09/2012</td>
<td>$145,674</td>
</tr>
</tbody>
</table>

### GROS, Philippe

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Genetic studies of blood stage malaria: from mouse models to human disease</td>
<td>04/2012-03/2017</td>
<td>$106,675</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Role of Vang1 proteins in normal development and in neural tube defects</td>
<td>10/2011-09/2016</td>
<td>$146,148</td>
</tr>
<tr>
<td>NIH (USA)</td>
<td>Investigator Initiated Research</td>
<td>Co-PI wBeauchemin</td>
<td>Genetic determinants of susceptibility to mycobacterial infections</td>
<td>04/2011-12/2015</td>
<td>$177,310</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Genetic control of susceptibility to colon cancer development</td>
<td>09/2012-08/2014</td>
<td>$10,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>Team Grant</td>
<td>wVidal</td>
<td>CIHR Team in ENU mutagenesis and infectious diseases</td>
<td>09/2008-08/2013</td>
<td>$150,000</td>
</tr>
<tr>
<td>GCRC, GQ and McGill U Innovation Centre</td>
<td>Team Grant</td>
<td>wVidal</td>
<td>Genomic analysis of the host: microbiota interface in the development of colitis and colorectal cancer</td>
<td>2012-2013</td>
<td>$10,000</td>
</tr>
</tbody>
</table>
### HALLETT, Michael

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH (USA)</td>
<td>PPG</td>
<td>wOstrowski</td>
<td>Genetic Analysis of the Breast Tumour Microenvironment</td>
<td>04/2012-03/2017</td>
<td>$33,750</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery</td>
<td></td>
<td>Signature Analysis Tools for the Life Sciences</td>
<td>04/2011-03/2016</td>
<td>$40,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>STIHR</td>
<td>wPark</td>
<td>Integrative Approaches to Human Health</td>
<td>04/2009-03/2015</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CQDM</td>
<td></td>
<td>wPark</td>
<td>Development of integrated tumor-microenvironment classifiers for personalized therapy targeting</td>
<td>09/2011-08/2014</td>
<td></td>
</tr>
<tr>
<td>QBCEF/CRS</td>
<td>Strategic Grant</td>
<td>wPark</td>
<td>Development of prognostic predictors integrating tumor-intrinsic and microenvironmental information and translation into clinical tests for ER-negative breast cancer</td>
<td>01/2012-12/2014</td>
<td></td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNFPPG</td>
<td>wMuller</td>
<td>Preclinical models and therapeutic targets for metastatic breast disease</td>
<td>04/2009-03/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>GQ</td>
<td>Genomics Research in Human Health</td>
<td></td>
<td>Next Generation Predictive Signatures for Breast Cancer</td>
<td>01/2011-12/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Pfizer fonds d’innovation</td>
<td>wPark</td>
<td>Tests prognostiques pour le cancer du sein basés sur l’immunohistochimie intégrant les composantes épithéliales et stromales</td>
<td>07/2010-07/2013</td>
<td></td>
</tr>
<tr>
<td>CCSRI</td>
<td>CBCCRA Predictive Oncology Grant</td>
<td>wPark</td>
<td>Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative disease</td>
<td>04/2011-03/2013</td>
<td></td>
</tr>
<tr>
<td>CIHR</td>
<td>Team Grant</td>
<td>wSzyf</td>
<td>Whole epigenome profiling of epigenetic marks of maternal depression and its impact on the offspring epigenome</td>
<td>04/2010-03/2013</td>
<td>$21,000</td>
</tr>
<tr>
<td>GQ</td>
<td>International Collaborations Program in Genomics</td>
<td>wBergeron</td>
<td>Proteomics of the Human Liver in Health and Disease</td>
<td>10/2011-09/2012</td>
<td>$12,750</td>
</tr>
<tr>
<td>GQ</td>
<td></td>
<td>wKimmins</td>
<td>Determining the role of the paternal epigenome in offspring health</td>
<td>08/2010-08/2012</td>
<td>$9,917</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Q-CROC</td>
<td>wBatist</td>
<td>Identification et validation de biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique</td>
<td>04/2009-03/2012</td>
<td>$4,250</td>
</tr>
</tbody>
</table>
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>POP</td>
<td>wNepveu</td>
<td>Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool</td>
<td>04/2011-03/2012</td>
<td></td>
</tr>
<tr>
<td>CIHR</td>
<td>Catalyst</td>
<td></td>
<td>Bioinformatics Approaches to cancer research</td>
<td>09/2009-08/2012</td>
<td>$22,000</td>
</tr>
<tr>
<td>NSERC</td>
<td>CHRP</td>
<td>wThomas</td>
<td>Chemical correctors of deltaF508 CFTR trafficking</td>
<td>04/2009-03/2012</td>
<td>$11,250</td>
</tr>
</tbody>
</table>

### JONES, Russell

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Defining and applying Oncometabolism</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>Catalyst Grant</td>
<td></td>
<td>Development of novel animal models to study the impact of metabolism on aging: Investigating the role of the AMP-activated protein kinase (AMPK)</td>
<td>04/2011-03/2012</td>
<td>$12,381</td>
</tr>
<tr>
<td>GQ</td>
<td>Large-scale project</td>
<td>wShore</td>
<td>Therapeutic development platform: targeting metabolism in cancer therapy</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>Arthritis Society of Canada</td>
<td>Operating</td>
<td>wShore</td>
<td>Metabolic control points in lymphomagenesis</td>
<td>07/2010-06/2013</td>
<td>$137,759</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Role of the AMP-activated protein kinase (AMPK) in stress resistance and cancer</td>
<td>04/2009-03/2013</td>
<td>$133,433</td>
</tr>
<tr>
<td>CFI</td>
<td>Leaders Opportunity Fund</td>
<td>wShore</td>
<td>Metabolism and Cancer: Studying the integration of metabolism and signal transduction in tumourigenesis</td>
<td>09/2009-08/2014</td>
<td>$32,000</td>
</tr>
</tbody>
</table>

### McCAFFREY, Luke

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Cell polarity in mammary morphogenesis and cancer</td>
<td>04/2012-03/2017</td>
<td>$110,138</td>
</tr>
<tr>
<td>TFF</td>
<td>New Investigator Award</td>
<td></td>
<td>Epithelial polarity in tumor invasion and metastasis</td>
<td>10/2011-09/2014</td>
<td>$146,371</td>
</tr>
<tr>
<td>Cure Foundation</td>
<td>Innovative Research Award</td>
<td></td>
<td>A role for PKC in stem cell renewal in Claudin-low breast cancer</td>
<td>01/2012-12/2012</td>
<td>$10,000</td>
</tr>
<tr>
<td>CFI</td>
<td>Leaders Opportunity Fund</td>
<td>wShore</td>
<td>Epithelial polarity in morphogenesis and cancer</td>
<td>01/2012-12/2012</td>
<td>$240,833</td>
</tr>
<tr>
<td>McGill</td>
<td>Start-up Funds</td>
<td></td>
<td>Epithelial polarity in mammary gland development and cancer</td>
<td>08/2010-07/2012</td>
<td>$55,416</td>
</tr>
</tbody>
</table>
### MULLER, William

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The role of ErbB2-14-3-3 sigma signaling axis in cancer and development</td>
<td>10/2010-09/2015</td>
<td>$155,694</td>
</tr>
<tr>
<td>NIH (USA)</td>
<td>Program Project</td>
<td></td>
<td>Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation</td>
<td>09/2010-08/2015</td>
<td>$191,580</td>
</tr>
<tr>
<td>CRS-QBCF</td>
<td>Strategic Grant</td>
<td></td>
<td>Integrin-mediated signal transduction in transgenic mouse models of human breast cancer</td>
<td>01/2012-12/2014</td>
<td>$149,987</td>
</tr>
<tr>
<td>NIH (USA)</td>
<td>Program Project</td>
<td></td>
<td>Mechanisms of breast cancer progression</td>
<td>09/2009-08/2014</td>
<td>$112,594</td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNFPFG</td>
<td></td>
<td>Preclinical models and therapeutic targets for metastatic breast disease</td>
<td>07/2009-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The role of Epidermal Growth Factor Receptor Family in mammary tumorigenesis and metastasis</td>
<td>04/2009-03/2014</td>
<td>$155,053</td>
</tr>
<tr>
<td>GQ</td>
<td>Research Grant</td>
<td>wHallett</td>
<td>Next Generation Predictive Signatures for Breast Cancer</td>
<td>01/2011-12/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The role of PI3K coupled signaling pathways in mammary tumorigenesis</td>
<td>08/2008-09/2013</td>
<td>$128,630</td>
</tr>
<tr>
<td>CBCRA</td>
<td>Research Grant</td>
<td></td>
<td>The role of ShcA and c-Src signaling pathways in ErbB-2 mammary tumor progression</td>
<td>07/2008-06/2013</td>
<td>$148,894</td>
</tr>
<tr>
<td>CIHR</td>
<td>Bridge Funding</td>
<td></td>
<td>Integrin-mediated signal transduction in mammary tumorigenesis and metastasis</td>
<td>10/2011-09/2012</td>
<td>$75,000</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Role of Akt family signaling in ErbB2 mammary tumour progression</td>
<td>09/2010-08/2012</td>
<td>$40,000</td>
</tr>
</tbody>
</table>

### NEPVEU, Alain

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Transcription and Tranlesion Synthesis</td>
<td>09/2009-08/2014</td>
<td>$139,935</td>
</tr>
<tr>
<td>NCIC</td>
<td>Operating</td>
<td>014288</td>
<td>Function and Modulation of CUX1 in Cell Cycle Progression</td>
<td>07/2008-06/2013</td>
<td>$136,448</td>
</tr>
<tr>
<td>CBCRA</td>
<td>Operating</td>
<td>014348</td>
<td>CUX1 in Mammary Tumors</td>
<td>07/2008-06/2013</td>
<td>$149,953</td>
</tr>
<tr>
<td>CIHR</td>
<td>Team Grant</td>
<td>CTP-79857</td>
<td>CIHR Team in Cancer Progression and Metastasis</td>
<td>04/2006-03/2011</td>
<td>$39,987</td>
</tr>
</tbody>
</table>

### PARK, Morag

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH (USA)</td>
<td>PPG</td>
<td>wOstrowski</td>
<td>Genetic analysis of the Breast Tumor Microenvironment</td>
<td>06/2012-05/2017</td>
<td>$111,606</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Role of Gab Family Signal Amplifiers in Tumorigenesis and Invasion</td>
<td>10/2010-09/2015</td>
<td>$154,481</td>
</tr>
<tr>
<td>QBCF/CRS</td>
<td>Strategic Grant</td>
<td></td>
<td>Development of prognostic predictors integrating tumor-intrinsic and</td>
<td>01/2012-12/2014</td>
<td>$150,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>microenvironmental information and translation into clinical tests for ER-negative breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CQDM</td>
<td></td>
<td></td>
<td>Development of integrated tumor-microenvironmental classifiers for personalized therapy targeting</td>
<td>09/2011-08/2014</td>
<td>$433,333</td>
</tr>
<tr>
<td>CIHR</td>
<td>SDRPS</td>
<td></td>
<td>Role of Crk Adapter Proteins in Cell Invasion and Metastasis</td>
<td>08/2008-07/2014</td>
<td>$150,000</td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNPFP</td>
<td>wMuller</td>
<td>Preclinical models and therapeutic targets for metastatic breast disease</td>
<td>07/2009-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Mechanisms of oncogenic activation of the met RTK in human cancer</td>
<td>10/2010-09/2013</td>
<td>$185,345</td>
</tr>
<tr>
<td>GQ</td>
<td>Research Grant</td>
<td>wHallett</td>
<td>Next Generation Predictive Signatures for Breast Cancer</td>
<td>01/2011-12/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Operating</td>
<td></td>
<td>Tests pronostiques pour le cancer du sein basés sur l'imunohistochimie intégrant les composantes épithéliales et stromales</td>
<td>07/2010-06/2013</td>
<td>$161,350</td>
</tr>
<tr>
<td>CIHR</td>
<td>CIHR Training</td>
<td>wHallett</td>
<td>Integrative Approaches to Human Health</td>
<td>07/2010-06/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CCSRI</td>
<td>CBCRA Predictive</td>
<td></td>
<td>Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative disease</td>
<td>04/2011-03/2013</td>
<td>$213,313</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Network Grant</td>
<td></td>
<td>Banque de tumeurs</td>
<td>04/2007-03/2012</td>
<td>$12,500</td>
</tr>
</tbody>
</table>

### PAUSE, Arnim

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Characterization of a novel pathway involved in energy/nutrient sensing</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Metabolic role of the tumor suppressor HD-PTP in lung tumorigenesis</td>
<td>09/2011-08/2013</td>
<td>$60,000</td>
</tr>
<tr>
<td>Myrovlytis Trust, UK</td>
<td>Operating</td>
<td></td>
<td>Functional Characterization of the Folliculin Tumor Suppressor Protein</td>
<td>07/2011-06/2013</td>
<td>$155,000</td>
</tr>
</tbody>
</table>
# Goodman Cancer Research Centre Annual Report 2012

**CCSRI Operating**
- Role of the inactive tyrosine phosphatase HD-PTP in cancer
  - 07/2010-07/2013
  - $138,000

**CIHR Operating**
- Investigating the mechanism of action of the von Hippel-Lindau tumor suppressor protein
  - 09/2007-08/2012
  - $95,867

**KFoC Operating**
- Functional characterization of BHD, a novel tumour suppressor gene involved in kidney cancer
  - 07/2010-06/2012
  - $25,000

## PELLETIER, Jerry

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>RNA Helicases in Tumorigenesis</td>
<td>04/2011-03/2016</td>
<td>$162,253</td>
</tr>
<tr>
<td>NIH (USA)</td>
<td>Operating</td>
<td></td>
<td>Targeting the DHX9 Helicase for Small Molecule Probe Discovery</td>
<td>08/2012-07/2015</td>
<td>$65,013</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Modelling Translation Initiation as Cancer Therapy</td>
<td>10/2010-09/2015</td>
<td>$159,410</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Innovation Grant</td>
<td></td>
<td>DHX9 – Evaluating a Novel Anti-Neoplastic Drug Target in Vivo</td>
<td>07/2012-06/2014</td>
<td>$50,000</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Operating</td>
<td></td>
<td>Chemical Dissection of Translation Initiation</td>
<td>07/2009-06/2014</td>
<td>$138,000</td>
</tr>
<tr>
<td>GQ</td>
<td>Large-scale project</td>
<td>wShore</td>
<td>Therapeutic development platform: targeting metabolism in cancer therapy</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CQDM</td>
<td>Operating</td>
<td>wShore</td>
<td>Integrated Platform: Synthetic Lethality in Cancer Therapy</td>
<td>07/2010-07/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>POP</td>
<td></td>
<td>Chemotherapeutic Agents for Inhibiting Protein Synthesis</td>
<td>09/2011-08/2012</td>
<td>$53,333</td>
</tr>
</tbody>
</table>

## SHORE, Gordon

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Bel-2 family Proteins, Cell Death and the Endoplasmic Reticulum</td>
<td>10/2010-09/2015</td>
<td>$261,747</td>
</tr>
<tr>
<td>GQ</td>
<td>Operating</td>
<td></td>
<td>Therapeutic Development Platform: Targeting Metabolism in Cancer Therapy</td>
<td>10/2010-09/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CQDM</td>
<td>Operating</td>
<td></td>
<td>Integrated Platform: Synthetic Lethality in Cancer</td>
<td>09/2010-08/2013</td>
<td>see Group Grants</td>
</tr>
</tbody>
</table>

## SIEGEL, Peter

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>GPNMB as an emerging therapeutic target in metastatic breast cancer</td>
<td>04/2012-03/2017</td>
<td>$110,680</td>
</tr>
</tbody>
</table>

20
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCSRI</td>
<td>Innovation Grant</td>
<td>wSaleh</td>
<td>Host genetic determinants of colon cancer metastasis</td>
<td>02/2012-01/2014</td>
<td>$0</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Research Grant</td>
<td></td>
<td>ShcA-dependent mechanisms driving breast cancer migration and invasion</td>
<td>07/2011-06/2014</td>
<td>$149,840</td>
</tr>
<tr>
<td>CCSRI</td>
<td>TFFNFPPG</td>
<td>wMuller</td>
<td>Preclinical models and therapeutic targets for metastatic breast disease</td>
<td>07/2009-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>GQ</td>
<td>Research Grant</td>
<td>wHallett</td>
<td>Next Generation Predictive Signatures for Breast Cancer</td>
<td>01/2011-12/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Defining Mechanisms by which CCN3 Promotes the Formation of Osteolytic Bone Metastases</td>
<td>09/2011-08/2013</td>
<td>$60,000</td>
</tr>
</tbody>
</table>

### SONENBERG, Nahum

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>elf4E phosphorylation and breast cancer: regulating tumour-host interactions and metastasis</td>
<td>10/2012-09/2017</td>
<td>$41,144</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td>114994</td>
<td>The role of mTOR pathway in translational regulation of synaptic plasticity, memory formation and disease</td>
<td>10/2011-09/2016</td>
<td>$199,637</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Mechanism of miRNA action in translation and mRNA decay</td>
<td>04/2009-03/2014</td>
<td>$156,927</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td>MHR-100848</td>
<td>Michael Smith Prize in Health Research</td>
<td>04/2009-03/2014</td>
<td>$100,000</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>mTOR inhibition and translation control of pancreatic neuroendocrine tumours</td>
<td>09/2011-08/2013</td>
<td>$60,000</td>
</tr>
<tr>
<td>CQDM</td>
<td>Operating</td>
<td>wShore</td>
<td>Integrated Platform: Synthetic Lethality in Cancer</td>
<td>09/2010-08/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Operating</td>
<td></td>
<td>Translational control in oncogenesis: Signaling to the translation initiation factor</td>
<td>07/2010-06/2013</td>
<td>$142,500</td>
</tr>
<tr>
<td>Autism</td>
<td>Operating</td>
<td></td>
<td>Regulation of neuronal translation in Autism Spectrum Disorders</td>
<td>02/2011-01/2013</td>
<td>$40,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td>MOP-7214</td>
<td>Mechanisms of translation initiation and control in</td>
<td>10/2007-09/2012</td>
<td>$179,935</td>
</tr>
</tbody>
</table>

21
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Team Grant</td>
<td>HET-85519 wCohen</td>
<td>CIHR Team ‘HIV Pathogenesis’</td>
<td>10/2007-09/2012</td>
<td>$90,337</td>
</tr>
<tr>
<td>NIH (USA)</td>
<td>Operating</td>
<td>2R01GM066157-05A2</td>
<td>Translational control by poly(A)-binding protein and its modulators (Paips)</td>
<td>07/2008-06/2012</td>
<td>$105,037</td>
</tr>
<tr>
<td>NCIC</td>
<td>TFFNFPPG</td>
<td>wBell</td>
<td>Canadian Oncolytic Virus Consortium</td>
<td>07/2007-06/2012</td>
<td>$94,008</td>
</tr>
<tr>
<td>CIHR</td>
<td>Catalyst Grant</td>
<td>IAB112229</td>
<td>The role of mTOR pathway in age-associated memory decline</td>
<td>04/2011-03/2012</td>
<td>$12,500</td>
</tr>
<tr>
<td>MDEIE</td>
<td>Programme de soutien à la recherche</td>
<td></td>
<td>Studying the mechanism of DAP5/p97 action in controlling cap-independent translation in eukaryotic cells</td>
<td>07/2009-06/2012</td>
<td>$25,000</td>
</tr>
</tbody>
</table>

### ST-PIERRE, Julie

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>The role of the PGC-1 transcriptional coactivators in the regulation of breast cancer metabolism</td>
<td>10/2010-09/2015</td>
<td>$131,088</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td>wTremblay</td>
<td>Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities</td>
<td>07/2011-06/2014</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>GQ</td>
<td>Concours santé-volet translationel</td>
<td>wShore</td>
<td>Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer</td>
<td>09/2010-08/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Fond d’établissement</td>
<td></td>
<td>The role of PGC-1 alpha in the regulation of cancer metabolism</td>
<td>07/2010-06/2013</td>
<td>$15,000</td>
</tr>
<tr>
<td>MCC</td>
<td>McGill-Weizmann partnership</td>
<td></td>
<td>Metabolism and DNA damage response</td>
<td>04/2011-03/2013</td>
<td>$80,000</td>
</tr>
<tr>
<td>GQ</td>
<td>Pilot project</td>
<td></td>
<td>Metabolomics of ErbB2-induced breast tumors</td>
<td>10/2010-09/2012</td>
<td>$75,000</td>
</tr>
</tbody>
</table>

### TEODORO, Jose

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>Assessment of PTEN-regulated Secreted Factors as Prostate Cancer Biomarkers</td>
<td>10/2012-09/2014</td>
<td>$15,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Tumour suppressor mediated mechanisms of angiogenesis inhibition</td>
<td>10/2011-09/2014</td>
<td>$127,510</td>
</tr>
</tbody>
</table>
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td>wBranton</td>
<td>Mechanism of Action of the Adenovirus Death Protein E4orf4 (JT share = $20,000/yr)</td>
<td>04/2009-03/2014</td>
<td>$20,000</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>Biology of Circoviruses</td>
<td>04/2009-03/2014</td>
<td>$40,000</td>
</tr>
<tr>
<td>Lamarre Townshend</td>
<td>Innovation Grant</td>
<td></td>
<td>Targeted Gold Nanoparticles for synergistic melanoma therapy</td>
<td>12/2012-11/2013</td>
<td>$1,666</td>
</tr>
<tr>
<td>CIHR</td>
<td>Dissemination events</td>
<td>wBranton</td>
<td>Montreal DNA Tumour Virus Meeting 2012</td>
<td>02/2012-01/2013</td>
<td></td>
</tr>
<tr>
<td>CIHR/NSERC</td>
<td>CHRP</td>
<td></td>
<td>Self Illuminating Nanoparticles for Melanoma Therapy</td>
<td>04/2010-03/2013</td>
<td>$42,000</td>
</tr>
<tr>
<td>Colon Cancer Canada</td>
<td>Operating</td>
<td></td>
<td>Role of the GOS2 Gene in progression of colorectal cancer</td>
<td>12/2011-11/2012</td>
<td>$45,833</td>
</tr>
</tbody>
</table>

### TREMBLAY, Michel

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>PTP-1b as a target in human cancer</td>
<td>04/2011-03/2016</td>
<td>$151,989</td>
</tr>
<tr>
<td>CCSRI</td>
<td>Operating</td>
<td></td>
<td>Understanding and targeting TC-PTP in immune diseases and cancer</td>
<td>07/2011-06/2014</td>
<td>$112,089</td>
</tr>
<tr>
<td>CIHR</td>
<td>TFNFPC</td>
<td></td>
<td>Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities</td>
<td>07/2011-06/2014</td>
<td>See Group Grants</td>
</tr>
<tr>
<td>QBCF/CBCRA</td>
<td>Operating</td>
<td></td>
<td>Role of the protein tyrosine phosphatase PRL-2 in breast cancer development and metastasis</td>
<td>01/2009-06/2014</td>
<td>$131,669</td>
</tr>
<tr>
<td>GQ</td>
<td>Large-scale projects</td>
<td>wShore</td>
<td>Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer</td>
<td>10/2010-09/2013</td>
<td>see Group Grants</td>
</tr>
<tr>
<td>DOD</td>
<td>CDMRP</td>
<td></td>
<td>Characterization of the oncogenic potential of protein tyrosine phosphatase 1B in prostate cancer</td>
<td>03/2009-02/2012</td>
<td>$25,532</td>
</tr>
</tbody>
</table>

### YAMANAKA, Yojiro

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
</table>

---

23
### Goodman Cancer Research Centre Annual Report 2012

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>Investigating the transition from head to trunk formation in vertebrate development</td>
<td>09/2012-08/2017</td>
<td>$18,153</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Cell polarity and generation of the first distinct lineages in the mouse embryo</td>
<td>04/2011-03/2016</td>
<td>$148,909</td>
</tr>
</tbody>
</table>

**YANG, Xiang-Jiao**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>Role of the sumoylation machinery in generating induced pluripotent stem cells</td>
<td>04/2012-03/2017</td>
<td>$25,500</td>
</tr>
<tr>
<td>CIHR</td>
<td>Operating</td>
<td></td>
<td>Role of a kinase-deacetylase-MEF2 signaling axis in normal and oncogenic cellular programs</td>
<td>10/2009-09/2014</td>
<td>$135,477</td>
</tr>
<tr>
<td>MDEIE</td>
<td>International Collaboration</td>
<td></td>
<td>Function and regulation of TAZ and YAP, two signal-responsive oncogene products</td>
<td>01/2010-12/2012</td>
<td>$50,000</td>
</tr>
<tr>
<td>CIHR</td>
<td>CIHR-China Collaboration Initiative</td>
<td></td>
<td>Role of epigenetic regulators in mediating anti-aging effects of PTHrP</td>
<td>01/2010-12/2012</td>
<td>$50,000</td>
</tr>
<tr>
<td>NCIC</td>
<td>Operating</td>
<td></td>
<td>Functional analysis of MOZ and MORF histone acetyltransferase complexes</td>
<td>07/2007-06/2012</td>
<td>$68,126</td>
</tr>
<tr>
<td>NSERC</td>
<td>Discovery Grant</td>
<td></td>
<td>Roles of a recurrent phospho-sumoyl switch in coordinated transcriptional control</td>
<td>04/2007-03/2012</td>
<td>$7,500</td>
</tr>
</tbody>
</table>

**ZANNIS-HADJOPOULOS, Maria**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSERC</td>
<td>Operating</td>
<td></td>
<td>Functional synergy between the DNA topology and DNA repair machineries during the initiation of DNA replication</td>
<td>07/2011-06/2016</td>
<td>$30,000</td>
</tr>
<tr>
<td>CRS</td>
<td>Operating</td>
<td></td>
<td>The role of Ku in breast tumorigenesis: Implications for therapy</td>
<td>09/2010-08/2012</td>
<td>$40,000</td>
</tr>
</tbody>
</table>

**ZOGOPOULOS, George**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Type</th>
<th>Grant #</th>
<th>Title</th>
<th>Funding Period</th>
<th>Amount 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Research Grant</td>
<td></td>
<td>The Genetics of Hereditary Upper Gastrointestinal Cancers: Beyond CDH1 Germline Mutations</td>
<td>09/2012-08/2017</td>
<td>$7,333</td>
</tr>
<tr>
<td>FRSQ</td>
<td>Establishment of Young</td>
<td></td>
<td>Changements génétiques et épigénétiques des cellules germinales, tumorales et du stroma dans les adénomes</td>
<td>07/2012-06/2015</td>
<td>$5,000</td>
</tr>
<tr>
<td>Researchers</td>
<td>pancréatiques</td>
<td>Start-up Operating Funds</td>
<td>08/2011-08/2014</td>
<td>$75,000</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>MUHC RI</td>
<td>NI Start-up Operating</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCRC</td>
<td>NI Start-up Operating</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MUHC</td>
<td>MGH Foundation/Canadian Surgical Research Fund</td>
<td>Genetic Susceptibility to Pancreas Cancer in Quebec</td>
<td>09/2012-08/2013</td>
<td>$10,000</td>
<td></td>
</tr>
<tr>
<td>GCRC/McGill Innovation Centre</td>
<td>Collaborative Project</td>
<td>Characterization of Germline Changes in Pancreatic Adenocarcinoma</td>
<td>10/2012-12/2012</td>
<td>$30,000</td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX IV

Publications (Jan-Dec 2012) – Total Number of Publications: 137
(including book chapters and reviews)

High Impact Papers – Yellow Highlight

BEAUCHEMIN, Nicole, Dr.


BOUCHARD, Maxime, Dr.
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bouchard%20M%22%5bAuthor%5d%20McGill


BRANTON, Philip, Dr.
URL: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=branton+pe%5BAuthor%5D%22


**DUCHAINE, Thomas, Dr.**
URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=Duchaine%20T%20%5bAuthor%5d](http://www.ncbi.nlm.nih.gov/pubmed?term=Duchaine%20T%20%5bAuthor%5d)

Caroline Thivierge*, Neetha Makil*, Mathieu Flamand, James Wohlschlegel, Jessica J. Vasale, Craig C. Mello, Darryl Conte Jr. and **Thomas F. Duchaine** (Corresponding Author). Tudor domain ERI-5 tethers an RNA-dependent RNA polymerase to DCR-1 to potentiate endoRNAi. Nat Struct Mol Biol. 19(1):90-7 (2012). (Published online 18 Dec 2011)

Reviews:


**GALLOUZI, Imed, Dr.**
URL: [http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=gallouzi+i%5BAuthor%5D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=gallouzi+i%5BAuthor%5D)


• This publication identifies Pateamine A as a potential therapeutic option to combat cancer-induced muscle wasting. Based on the promising nature of our findings, the manuscript has been the subject of major news coverage (see below). It was also highlighted by the Canadian Cancer Society as one of the top 10 research achievements of 2012. Website: [http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2012/Top%2010%20Society-funded%20research%20of%202012.aspx](http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2012/Top%2010%20Society-funded%20research%20of%202012.aspx)


Peer Reviewed Invited Reviews:


Book chapter:

GIGUERE, Vincent, Dr.


GROS, Philippe, Dr.


HALLETT, Michael, Dr.
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hallett%20M%22%20Author%5D%20cancer


JONES, Russell, Dr.
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jones%20RG%22%5BAuthor%5D


McCaffrey, Luke, Dr.


McCaffrey, L., Montalbano, J., Mihai, C., Macara, I.G. (2012) Loss of the Par3 Polarity Protein Promotes Invasion through aPKC-dependent Induction of Stat3. *Cancer Cell.* 13;22(5):601-14. I conceived the experiments, contributed 12/14 figures and co-wrote the paper. JM contributed 2/14 figures. CM performed experiments for the revision. IGM conceived experiments and co-wrote the paper. All revisions were completed in my lab at McGill. Corresponding author. *Member of my lab at McGill.*

Muller, William, Dr.


Li, J. Karaplis, A. C., Huang, D. C., Siegel, P. M., Camirand, A., Yang X.F., Muller, W.J. and Kremer, R. (2012). PTHrP drives breast tumor initiation, progression and metastasis in mice and is a potential therapy target. *JCI* 121.4655-4669. PMID 22056386


Lahlou, H., Sanguin-Gendreau, V., Frame, M.C., and Muller, W. J. (2012). Focal Adhesion Kinase


NEPVEU, Alain, Dr.


Book chapter:

PARK, Morag, Dr.
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%22Park%20M%22%5bAuthor%5d%20McGill


PAUSE, Arnim, Dr.
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=Pause%20A%20%5bAuthor%5d


PELLETIER, Jerry, Dr.


SHORE, Gordon, Dr. URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shore%20GC%22%5BAuthor%5D%20McGill

Natasha C. Chang; Mai Nguyen; Johanne Bourdon; Paul-Andre Risse; James Martin; Gawiyou Danialou; Rosario Rizzuto; Basil J. Petrof; Gordon C. Shore. Bel-2-Associated Autophagy Regulator Naf-1 Required for Maintenance of Skeletal Muscle  Human Molecular Genetics 2012; doi: 10.1093/hmg/dds048


SIEGEL, Peter, Dr. URL: http://www.ncbi.nlm.nih.gov/pubmed?term=Siegel%20PM%20%5bAuthor%5d


S. Tabariès, F. Dupuy, Z. Dong, A. Monast, M.G. Annis, J. Spicer, L.E. Ferri, A. Omeroglu, M. Basik,
Goodman Cancer Research Centre Annual Report 2012


SONENBERG, Nahum, Dr.


Morita, M., Ler, L.W., Fabian, M.R., Siddiqui, N., Mullin, M., Henderson, V.C., Alain, T., Fonseca,


Books (Editor):


Reviews and Book Chapters:


Deblois, G., St-Pierre, J. and Giguère, V. (2012). The PGC-1/ERR signaling axis in cancer. Oncogene Dec 3 (doi: 10.1038/onc.2012.529). Impact factor: 6.4; Pubmed ID: 23208510. This review covers the recent development in the understanding of the metabolic roles of ERRs and PGC-1s in cancer. I participated to the writing of the sections on PGC-1s and to the elaboration of novels concepts and future research directions presented in the manuscript.


conception, execution and interpretation of the cellular respiration measurements. Also, I wrote the corresponding sections in the manuscript.

Javeshghani, S., Zakikhani, M., Austin, S., Bazile, M., Blouin, M.J., Topisirovic, I., St-Pierre, J. and Pollak, M.N. (2012). Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Research 72 (23), 6257-6267. Impact factor: 7.9; Pubmed ID: 23041548. We performed all the respiration experiments presented in the manuscript and wrote the corresponding sections.


St-Pierre, J. and Tremblay, M.L. (2012). Modulation of leptin resistance by protein tyrosine phosphatases. Cell Metabolism 15 (3), 292-297. The two authors are joint corresponding authors. Impact factor: 13.7; Pubmed ID: 22405067. This review presents the role of specific phosphatases in the development of leptin resistance. Dr. Tremblay took a leading role for the sections of the manuscript covering signaling, while I took charge of the sections on leptin resistance and metabolism. Dr. Tremblay and myself wrote the manuscript and elaborated the figures together. We are both corresponding authors on this review.

TEODORO, Jose, Dr.
URL:  http://www.ncbi.nlm.nih.gov/pubmed?term=Teodoro%20J.G%20%5bAuthor%5d


TREMBLAY, Michel, Dr.
URL:  http://www.ncbi.nlm.nih.gov/pubmed?term=Tremblay%20ML%20%5bAuthor%5d


YANG, Xiang-Jiao, Dr.


Invited Reviews:

ZANNIS-HADJOPOULOS, Maria, Dr.  
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=Zannis-Hadjopoulos%20M%20%5bAuthor%5d


ZOGOPOULOS, George, Dr.  
URL: http://www.ncbi.nlm.nih.gov/pubmed?term=Zogopoulos%20G%20%5BAuthor%5D%20

APPENDIX V

Involvement in the Community 2012

BEAUCHEMIN, Nicole

Committees
Co-director of the McGill Integrated Cancer Research Training Program (MICRTP), jointly funded by CIHR and FRSQ. 56 investigators and 250 trainees. September 2006-present. THIS TASK REQUIRES ONE DAY/WEEK OF WORK.
Member of search committee for administrators in Goodman Cancer Research Centre, Sept. 5, 2012.
Chair of the Training committee for the Goodman Cancer Research Centre, 2010-present.
Member of the Dept. of Oncology Financial Oversight committee. 2012-present.

Conference Organization
Chair and co-organizer of the Montreal International Symposium on Angiogenesis and Metastasis (MISAM 2013). Responsible for grant writing, scientific program and coordination of 2.5 day event for June 12-14 2013 for 150 Quebec, Canadian and international attendees.
I was also participating in the organization of the meeting Signalisation-Quebec in Trois-Rivières in 2012. This meeting brings together all researchers in Quebec using Molecular Signaling as a readout of their phenotypic experiments.

Grant Panels
Canadian Institutes for Health Research, 2011 – present, Chair: Cancer Progression and Therapeutics committee. This committee requires 10 days of work other than reviewing. I make it a point to read and evaluate all grants submitted to our panel i.e. 90 grants/year.

Journal Reviews
at least 10 reviews for various journals/year

Community Outreach
Goodman Cancer Centre Public Forum, Organizer and Moderator for 2012-2013.

Invited Presentations and Workshops
Queen’s University, Dept. of Biochemistry, seminar, Kinston, ON, October 2012
Canadian Digestive Disease Week, Symposium, Feb. 2012
Signalisation-Québec, June 2012
22nd CEA International Symposium, Clermont-Ferrand, France, June 2012
40th annual meeting of International Society for Oncology and Biomarkers (ISOBM), Jerusalem, Israel, October 2012. KEYNOTE ADDRESS

BOUCHARD, Maxime
Ad hoc reviewer
NSERC, Dec 15, 2012

Editorial Boards
ISRN Nephrology, April 2012

Internal Committees
Member, Imaging facility, Life Science Complex, May 2004- present
Member, Histology facility committee, Life Science Complex, May 2004- present
Member, Financial Committee, Goodman Cancer Research Centre, May 2004- present
Member, Graduate Admission Committee, Biochemistry, Sept. 2004- present
  Evaluate Ph.D. proposal of every graduate student registered in Biochemistry (1-2 days of student presentations per semester; over 60 students to date)
  Decide on new programs and policies for the Biochemistry graduate program
  Establish course requirements for newly admitted graduate students
Member, Executive Direction Committee, Division of Experimental Medicine, Faculty of Medicine, Jan. 2007- present. Decide on new Associate members to join in the Division; decide on policies and regulations for the Division.

Invited speaker
20th Meeting of the EUA section of Urological Research (ESUR), Anti-oncogenic role of Gata3 in prostate cancer. Oct. 25-27, 2012, Strasbourg, France
Conference: Immunity Epigenetics and Cancer, Gata3 in prostate development and cancer. Research Institute for Molecular Pathology, Oct. 18-19, 2012, Vienna, Austria
Lady Davis Institute, Anti-oncogenic role of Gata3 in prostate cancer” March 22, 2012, Montreal

BRANTON, Philip

Panels, Boards and Councils
2006-present Chair, International Advisory Board, University Hospital Network, University of Toronto
2008-present Member, National Research Council Cancer Advisory Committee, Protein Therapeutics Group, Biotechnology Research Institute, Montreal, QC
2008-present Chair, Scientific Advisory Committee, Terry Fox Research Institute
2010-2012 Member, Lady Davis Research Institute Recruitment Search Committee
2010-present Chair, Jewish General-Goodman Cancer Research Centre Liaison Group
2010-present Member, Advisory Board, Canadian Tumour Repository Network
2010-present Member, Review Board, Integrated Cancer Research Sites (SIRIC), Institut national du cancer (INCa, Paris, France)
2011-present Member, Executive Committee, Goodman Cancer Centre, McGill University
2012 Chair, Review Committee for the Department of Medical Biophysics, University of Toronto
2012 Member, Alberta Innovates Health Solutions-Industry Partnered Translational Fund Advisory Panel
2012-2013 Chair, Brain Canada Training Award Panel
2012-present Chair, FRQS Committee for the creation of a Quebec Tumour Bank Network
2012-2013 Chair, Terry Fox Research Institute Consultation Committee on Program Project Grants

Internal Committees
DUCHAINE, Thomas

Invited speaker
Apr 2012 Messenger RNA Deadenylation in MicroRNA-Mediated Silencing and RNAi, Dept. Biology, NYU
Feb 2012 microRNAs and 3’ untranslated regions: a silent dialogue in the embryo, Keystone International Symposium: Gene Silencing by Small RNAs

Journal Reviews
Molecular Cell, NSMB, Cell, RNA, Science, PNAS, DNA & Cell Biology, PloS One, PloS Genetics, Nucleic Acid Research, WIREs Developmental, Biology

Grant Reviews
2011-2012 CIHR, Molecular and Cellular Biology of Cancer, Member and Scientific Officer
2011-2012 FRSQ, Postdoctoral Fellowships, Member

Internal Committees
Goodman Cancer Research Centre finances committee, Member, April 2009 – present.
Faculty of Medicine internal grant review, Reviewer, Fall 2012.
Lady Davis (McGill) faculty recruitment committee, Invitee external member, 2 candidates in Fall 2012.
McGill Integrated Cancer Research Training Program (MICRTP), Interim co-Chair, August 2012.
Graduate Admission Committee, PhD proposal Panel member, June 7, 2012, 3 reviews

GALLOUZI, Imed

Grant/Studentship Agencies
CIHR, permanent member of BCA panel as of Sept 2009 competition
FRSQ, Internal reviewer, Junior 1 salary awards, Feb. 2012
CIHR, NCIC, NSERC, NIH, CRC external reviewer
Alberta Heritage Found. for Medical Research, National Science Found., USA, American Federation for Aging Research and Prostate Cancer Foundation of Australia, Jesse’s Journey Foundation , Heart and Stroke Foundation

Grant panels
Reviewer for a CRC (Canadian Research Chair) Tier I, 2012
Regular reviewer for CRC (Canadian Research Chair) TierII. I reviewed several CRC TierII applications. 2006-present
NSERC, external reviewer for several Discovery Grants, 2005- present

External Reviewer for International Funding Agencies
Genesis Oncology Trust, New Zealand, external reviewer, 2012
Goodman Cancer Research Centre Annual Report 2012

Member of the scientific board of the American Federation for Aging Research (AFAR), Baltimore, Bethesda, USA. I serve as reviewer for several operating grants and postdoctoral Fellowships, 2009-present
Prostate Cancer Foundation of Australia (PCFA). external reviewer for several operating grants each round, 2009-to-present

Editorial Boards
Editor for PLoS One, 2011-present
Editor Aging, 2010-present

Invited speaker
Pateamine A, an Inhibitor of General Translation, Prevents Cachexia-Induced Muscle Wasting.
Seminar at the Universite de Laval, Quebec City, Quebec March 22-23, 2012.
Pateamine A, an Inhibitor of General Translation, Prevents Cachexia-Induced Muscle Wasting.
Seminar at the Meakins-Christie Laboratories, McGill University, Montreal, Quebec Sept 1, 2012.

Internal Committees
MICRTP, Studentship review, Goodman Cancer Research Centre, 2011-2012
Chair of the Graduate Advisory Committee (GAC), Department of Biochemistry, 2009-present
Member of the Graduate Advisory Committee (GAC), Department of Biochemistry, 2002-present
Member of the Departmental Tenure Committee (DTC), Department of Biochemistry, 2008-present
Member of Goodman Cancer Centre Space and Equipment Committee (Chair: Dr. Alain Nepveau), 2012-to-present
Member of Department of Biochemistry space committee, 2010-to-present

External Reviewer for Tenure dossiers
2012, Dr. Nadine Wiper-Bergeron, Department of Cellular and Molecular Medicine, University of Ottawa, ON, Canada

Activities outside McGill University

University of Taibah, Al-Madinah, Kingdom of Saudi Arabia
In 2011, Dr. David Thomas and I were approached by Dr. Kahled Al-Harbi from Taibah University, Al-Madinah Almunawwarah, Kingdom of Saudi-Arabia to help them in building the Centre for Genetics & Inherited Diseases (CGID). With Dr. Thomas I helped organizing several Visits for Dr. Al-Harbi to McGill and initiate contacts with University officials. I was also part of a team headed by Dr. D. Thomas that went to Al-Madinah in April 2012 to take part in the first international meeting for Genetics & Inherited Diseases that served as launching event for this project. This project in now underway and I am actively involved in the ongoing negotiation between McGill University, Taibah University and the CGID to put in place a service agreement with that will serve as a basis for this collaboration.

Invited to take part in the editing of the 1st Canadian edition of the Garrett and Grisham “Biochemistry” text book which will be launched in 2012
In 2010 I was approached by Nelson Education Ltd to help edit the “BIOCHEMISTRY” book for undergraduate students by Garrett and Grisham that will be launched as the first Canadian Edition of this book. I am one of the three professors that were hired for this task. The original task was to edit and update 10 to 11 chapters out of 32, with an emphasis of highlighting findings of Canadian scientists when appropriate. In addition, after my initial assessment of the content in various books covering Biochemistry, Molecular and Cellular Biology, I noticed that none of them, including the
Garrett & Grisham book, dedicates a chapter describing the mechanisms impacting gene expression at the posttranscriptional level. Therefore, I suggested to the editor to include such a chapter in the 1st Canadian edition of this book. The editors and my co-authors agreed and supported the idea.

The book is now at its final stage and will be launched in November 2012. I completed the new chapter that was reviewed and highly commended by my co-authors as well as one of the world leaders in the posttranscriptional regulation of gene expression field, Dr. Jack Keene from Duke University, USA.

GIGUERE, Vincent

Editorial Boards

Grant Reviews
CCSRI Innovation Grant Panel I1b, Gene Expression, Member (2012)

Meetings
Poster Judge Competition, 94th Annual Meeting of the Endocrine Society, Houston, TX, USA, June 2012.

Invited Speaker
March 2012. Invited speaker, Educational Sessions on “Nuclear Receptors as Therapeutic Targets in Cancer, American Association for Cancer Research Annual Meeting, Chicago, Illinois, USA.
May 2012. Invited speaker, La Cité de la Biotech 10th Anniversary Symposium, Montréal, QC, Canada.
June 2012. Invited speaker, Annual Meeting of the Endocrine Society, Symposium on “Nuclear Receptors and Metabolic Diseases”, Houston, Texas, USA.

GROS, Philippe

Grant Reviews
CIHR, Panel Member, Knowledge Diffusion Grant Committee (2011-present)
Canadian Gene Cure Foundation, Panel Member, Champions of Genetics Program (2010-on)
Burroughs-Wellcome Fund, Advisory Committee, “Investigators in Infectious Diseases Program” (2003-Present)

Governance
Canadian Institutes for Health Research, Knowledge Diffusion Panel (2010-)
McLaughlin-Rotman Center for Global Health, University Health Network, University of Toronto, Member, External Advisory Board (2004- Present)
Canadian Genetic Diseases Network (CGDN), Scientific Director (2005- 2007)
Canadian Gene Cure Foundation, Scientific Director (2007-Present)
Bill and Melinda Gates Foundation, Grand Challenges Explorations Program (Evaluation Panel)
Patents

Internal Committees
Search committee for recruitment into the Life Sciences Complex, McGill University, Faculty of Medicine
Planning Committee, Strategic Research Plan, McGill University, Faculty of Medicine
Management Committee, Transgenic Core Facility, McGill University, Goodman Cancer Research Centre

Invited Speaker, Scientific Meetings
ASM Biodefenses and Emerging Diseases Research Meeting, Washington, DC, USA; February 26-29, 2012; “Host Genetic Resistance to Mycobacterial Infections: The Case of Mycobacterium tuberculosis”
New Perspective in Immunity and Infection, Heidelberg, Germany; May 19-22, 2012 “Role of IRF transcriptional regulators in response to infection and in acute inflammation”
Infectious Diseases Society of America; “Advancing science, improving care” San Diego, CA, USA; October 17-21, 2012 “Susceptibility to Mycobacterial Infections: IRF8 and Beyond”
Annual Symposium on Primary Immunodeficiency Diseases, Newport Beach, CA, USA; November 3-4, 2012 “Human dendritic cell immunodeficiency”

Invited Speaker, Institutions
Genome Quebec, and McGill University Innovation Center annual retreat, Montreal, QC January 27, 2012 (Dr. M. Lathrop). Genetic effects in susceptibility to intracellular pathogens: Genome-wide screen in ENU-mutagenized mice.
UCLA, Dept. Physiology (Dr. R. Kaback) October 17, 2012. “Genetic control of susceptibility to infections: from mouse to man”.
Montreal Symposium on Novel Therapeutic Avenues in Tuberculosis, Montreal, QC, October 30, 2012. “IRF8 deficiency and susceptibility to infection with mycobacteria”.

HALLETT, Michael

Grant reviews

Conference committees
Canadian Institute of Health Research (CIHR) Genomics, Ottawa, 2012 (now Chair)
Canadian Partnership Against Cancer, Toronto, 2012
Meeting organization
I am the principle organizer of an annual workshop at the McGill Bellairs Research Centre in Barbados (http://www.mcb.mcgill.ca/research/comblab/barbados). Each year I choose a co-organizer who is an expert in the field and invite between 15 and 20 international researchers. 11th Meeting 2012 - Deciphering the Syntax of Gene Regulation T Hughes, University of Toronto

Invited speaker
2012 Radiation Hospital, Oslo, Norway (April 2012) The Illusion of Accuracy in Breast Cancer Prognosis

JONES, Russell

Director, McGill University Flow Cytometry Core Facility, 2009 – present

Meetings organized
Co-organizer, FASEB Summer Research Conference: AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities, Asilomar, CA, USA, October 7-12, 2012

Grant reviews
Member, Cancer Research Society (CRS) review panel, 2012
Member, CIHR grant panel: Cancer Biology and Therapeutics, 2009 – present

Internal Committees
Member, Defi Canderel Studentship and Fellowship Grant Committee, Goodman Cancer Research Centre, McGill University, 2008 – 2012
Member, Faculty of Medicine Studentship and Fellowship Grant Committee, McGill University, 2008 – 2012
Member, Downtown FACC (Animal Care Committee), McGill University, 2008 – 2012

Ad Hoc Reviewer for Journals

McCAFFREY, Luke

Journal Reviews
2009 – 2012 Journal of Cell Biology (reviewed 3 manuscripts)
2009-present Faculty of 1000
2011 – 2012 Molecular Cell (reviewed 1 manuscript)

Grant Panels
2011-2013 Reviewer, Panel C, Cancer Research Society
2012-2013 Reviewer, Panel A, Canadian Breast Cancer Foundation – Ontario Region
Internal Committees
2010-Pres. Member, McGill Integrated Cancer Research Training Program Committee
2011-Pres. Chair, Canderel Committee
2011-Pres. Member, Histology Core Committee
2012-Pres. Member, GCRC Training Committee

Invited speaker
2012 "Disrupted Par3/aPKC Polarity Signaling Promotes Breast Tumourigenesis and Metastasis" Terry Fox Research Institute Annual Scientific Meeting, Victoria, BC.
2012 "Challenges in Collaborative Research: A New Investigator's Perspective". Terry Fox Research Institute Annual Scientific Meeting, Victoria, BC.

MULLER, William

Grant Panels
2000-present Member, Scientific NIH PPG Advisory Panel, UCSF
2001-present Member, Scientific NIH PPG Advisory Panel, Ohio State
2002-present Member, Scientific NIH Advisory Panel, Albert Einstein School of Medicine
2005-present Member, US Army Integration Panel
2010-present Chair of CRS Panel D

Ad hoc Journal Reviews

Invited Speaker
Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Think Tank 22, Cancun, Mexico, Jan 15-21, 2012.
Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Think Tank 22, Cancun, Mexico, Jan 15-21, 2012.
NEPVEU, Alain

Editorial Board
Editor, Gene, 2011-present

Grant reviews
CRS 2012, Tumour Suppressor Genes, Oncogenes and DNA Repair

Studentship and Fellowship Review Panels
McGill University Health Center Research Institute, Studentships and Fellowships, 2007-2012

Public Awareness
"Relais pour la vie de Gatineau 2012", at the Centre Asticou, 241, Boulevard de la Cité-des- Jeunes, Gatineau, Québec. On this occasion, I gave a seminar to the survivors and their families.

Internal Committees
Recruitment Committee, Goodman Cancer Center, Chairman, 2008-2012
Promotion Committee, Department of Oncology, 2011- present
Space and Equipment Committee, Goodman Cancer Centre, Chairman, 2012-present

Invited speaker
Aug 2012 Guest of the students, Journée scientifique des étudiants, Hôtel-Dieu de Québec
Aug 2012 Gordon Research Conference on Mutagenesis, Salve Regina University, Newport,
June 2012 Centre du Cancer Paul Papin, Angers, France
June 2012 Université de Lyons, France
May 2012 First Canadian Symposium on Telomeres & Genome Integrity
Feb 2012 Workshop on Bioinformatics in Transcription, Belairs Research Station, Barbados.

PARK, Morag

Professional and Scientific Contributions
Member, Gairdner Foundation Medical Review Panel, 2011-2014
Member, Cancer Stem Cell Consortium (CSCC), 2008-present
Member, WHO-International Agency for Cancer Research (IARC), Governing Council, Lyon, France, 2008-present

Site Visits and Advisory Panels
2012 Arizona Cancer Centre, Strategic Review

Internal Committees
Faculty of Medicine Search Committee, Member for Chair of Oncology
Steering Committee for Strategic, Member, Research Priorities, Faculty of Medicine
Gerald Bronfmann Centre Merit Awards, Member
Goodman Cancer Centre, Finance Committee, Chair, 2009-present
Invited speaker, International

Dec 2012 Invited speaker, CTRC-AACR, San Antonio Breast Cancer Symposium, San Antonio, Texas, USA
Nov 2012 Invited speaker, 43rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan
Oct 2012 Invited speaker, Ohio State University, Ohio, USA
Aug 2012 Invited speaker, Salk Post Translational Regulation of Cell Signaling, Salk Institute, La Jolla, California, USA
July 2012 Invited speaker, FASEB Science Research Conference, Snowmass Village, Colorado, USA
Apr 2012 Invited speaker, Annual American Association for Cancer Research Meeting, Chicago Illinois, USA
Mar 2012 Invited speaker, MCB/CMM Department Seminar, The University of Arizona Cancer Center, Tucson, Arizona, USA

Invited speaker, National

Nov 2012 2nd Annual Gerald Bronfman Centre Symposium and Awards Ceremony, Montreal Neurological Institute and Hospital, Montreal, QC, Canada
Feb 2012 Invited speaker, BC Cancer Agency Research Seminar, Vancouver, BC
Feb 2012 Invited speaker, Science Talks about Research for Staff (STARS) Lecture Series, McGill University, Montreal, QC, Canada
Feb 2012 Invited speaker, Ontario Institute of Cancer Research and McMaster University, Toronto and Hamilton, ON, Canada

PAUSE, Arnim

Grant Panels

2012 Peer reviewer of Medical Research Council (UK) Operating grant
2012-present Member of Operating Grant Panel of Romanian National Council for Scientific Research
2012-present Member in Defi Cancerel Defi Cancerel Studentship and Fellowship Grant Committee, McGill Cancer Center MUHC, Oncology, and other biomedical departments.
2010-present Member in Operating Grant Panel of the Kidney Foundation of Canada
2009-present Member of Research Award Committee of von Hippel-Lindau Family Alliance
2008-present Member of the Research Award Committee of the Canadian Liver Foundation
2005-present Member of the College of Reviewers for CRC chairs
2007-present Reviewer for the Saskatchewan Health Research Foundation
2005-present Mentor and Member of the Canadian National Hepatitis C Research Training Program (NCRTP-HepC).

Conference organizing

2012 Invited speaker, Member of the Scientific Committee, and Session Chair: The Fourth Birt-Hogg-Dube (BHD) Symposium, Cincinnati, USA.
**Internal Committees**

- 2012-present: Member of Education Committee of the Goodman Cancer Research Centre
- 2012-present: Coordinator of the Website of the Goodman Cancer Research Centre
- 2011-present: Committee for hiring of a PI for Cancer Metabolism in the Goodman Cancer Research Centre
- 2012-present: Committee for hiring a senior administrator and a senior scientific administrator and fundraiser for the Goodman Cancer Research Centre

**Scientific Advisory Boards**

- 2012-present: Member of SAB Myrovlytis Trust, UK.
- 2010-present: Member of SAB for Proreo Pharma Innovation AG, Basel, Switzerland.
- 2006-present: Consultant for Insymbiosis Discovery, Inc. Montreal, Canada.

**Invited speaker**

- 2012: Speaker at the FASEB meeting on: “AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities”. Pacific Grove, California
- 2012: Invited speaker, Member of the Scientific Committee, and Session Chair: The Fourth Birt-Hogg-Dube (BHD) Symposium, Cincinnati, USA.
- 2012: Invited Speaker at VHL Medical Symposium, MD Anderson Cancer Center, Houston, TX, USA.

**PELLETIER, Jerry**

**Patents**


**Grant reviews**


**Internal Committees**


Member of Chemical Biology Studentship Evaluation Panel (2003-Present). In 2012, we meet June 6th, Dec 11th, and Dec 12th.

**Invited speaker**


**SHORE, Gordon**

**Invited speaker**

8th International Barbados Workshop: From Molecular Cell Biology to Clinical Proteomics, Folkestone, Feb 21, 2012
SIEGEL, Peter

Grant reviews
2012 CBCF/CIHR – Breast Cancer in Young Women, CBCF/CIHR – Workshop
2012, 2013 Research Grant Competition, CRS (Panel C2, Chair)
2012, 2013 Research Grant Competition – Impact, CCSRI

Internal Committees
Goodman Cancer Research Centre
Interim Director, 03/2012-06/2013
Oversee the general operation of the GCRC, conduct evaluations of faculty, oversee administrative (15) and research (12) staff, and serve as chair/member of several committees within the Centre (9 active committees).
Strategic Planning Committee, 2012-present
Finance Committee, 2011-present
Equipment and Space Committee, 2010-present
Recruitment Committee, 2012-present
Histology Core Committee, 2009-present

Faculty of Medicine
Faculty Leadership Council, 2012 – present
Bellini Search Advisory Committee, 2012 – present
Oncology Management Committee, 2012 – present
Search Committee – MNH (Neurosurgeon recruit), 2012 – 2013
Search Committee – Herbert Black Chair (Surgical Oncology), 2012 – 2013

Invited speaker
(2012, Feb.) Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada
(2012, Apr.) BONUS7 (Breast Cancer and Bone Disease Updates), National Arts Centre (Ottawa), Ottawa, Canada
(2012, June) Cancer Seminar Series, Lady Davis Institute, McGill University, Montreal, Quebec
(2012, June) Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York

SONENBERG, Nahum

Committee Memberships/Editorship
2008-present External Advisory Board – MRCE (Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research)
2010-present Editorial Board, WIRES RNA
2011-present Editorial Board, Current Opinions in Cell Biology

Editor
Meetings Organized

Invited Presentations
Cold Spring Harbor Laboratory, N.Y. “Downstream of mTOR”.
Brandeis University March 29, 2012. Waltham, MA. Lewis S. Rosenstiel Award Lecture “Translational control of cancer, learning and memory”.
mRNA fate workshop” Life and Death of mRNA in the Cytoplasm. Riva del Garda, Italy. May 23-26, 2012. Invited Speaker-Keynote Lecture and Session Chair.
Symposium on RNA pathobiology in cancer. Medical University of South Carolina, Charleston, SC. June 7th, 2012. Invited Session Chair and Speaker. “Translational control of cancer”.

ST-PIERRE, Julie

Editorial Board
Médecine Sciences Amérique (MSA) Journal, 2012-present

Grant Panels
Cancer Research Society, Panel D: tumor progression and metastasis, ~40 hours of grant review and 2 days meeting per year, 2010-2012
Fonds de la Recherche en Santé du Québec, Comité des bourses de formation postdoctorale, ~40 hours of application review and 2 days meeting per year, 2011-2013
Canadian Institutes of Health Research, Panel Cancer Progression & Therapeutics, ~40 hours of grant review and 2 days meeting per year, Fall 2011, Fall 2012, Spring 2013

University Administration
Scientific Director of the metabolomics platform, Goodman Cancer Research Centre, 01/2010-present.
McGill Representative, Co-trustee for the charitable trust (Michael D’Avirro succession) that was given to the Goodman Cancer Research Centre, 2009-present
Internal Committees
Academic Committee for McGill University, Member, ~18 hours/year, 2010-present
Postgraduate Awards Committee, Faculty of Medicine, Reviewer, 25 hours/year, 01/2011-12/2014
Junior Seminar Evaluation Committee, Department of Biochemistry, McGill University, Examiner, ~10 hours/year, 09/2008-present
Teaching Committee, Department of Biochemistry, McGill University, Member, ~3 hours/year, 2012-present
Recruitment Committee, Goodman Cancer Research Centre, Member, ~10 hours/year, 2011-present
Equipment and Space Committee, Goodman Cancer Research Centre, Member, ~5 hours/year, 2012-present

Evaluator for Poster Session at Conference

Invited speaker
PGC-1alpha at the crossroads of metabolism and cancer. 'Chewing the Fat' symposium in Honor of Dr. Bruce Spiegelman. Harvard Medical School, Boston, USA, November 2, 2012.
Metabolic regulation by the PGC-1 transcriptional coactivators. Research Awareness Day, Department of Biochemistry, McGill University, Montréal, Canada, September 22, 2012.

TEODORO, Jose

Editorial Board, Oncology Letters, 2009-present

Grant Panels
Cancer Research Society, 2008-2010, Panel C: Tumor suppressor genes, Oncogenes and DNA Repair. Returned to panel in 2012. 2 meeting days/year.
CIHR Molecular and Cellular Biology of Cancer (MCC), panel member, 2010-present
Fonds de la recherche en santé (FRSQ) Junior 1 Salary Awards 2010-present

Meetings organized
Organizer of the 2012 International DNA Tumour Virus Meeting

Ad hoc Journal reviews
Trends in Microbiology, Apr 2012.

Internal Committees
Goodman Cancer Centre Safety Committee, Chair, April 2007-present
Goodman Cancer Centre Finance Committee, 2011-present
Goodman Cancer Centre Research and Space Management Committee, 2008-present
Coordinator of the Goodman Cancer Research Centre Seminar Series, 2009-present
Goodman Cancer Centre Space and Equipment Committee, 2012-present. 10 hours/year
Goodman Cancer Research Centre Annual Report 2012

Invited Speaker
McGill University, Department of Microbiology and Immunology, Montreal, Quebec, Topic: Induction of Tumour-Specific Cell Death by Viral Targeting of the Anaphase-Promoting Complex. April 2012. (Invited by Dr Joaquin Madrenas)

TREMBLAY, Michel

Grant panels
At my return to Montreal in late September I had accepted to serve on the CIHR Operating grant panel: grant panel MCC panel held in the fall 2012.

Journal Reviews
During the sabbatical I maintain all my duties of ad-hoc reviewers including in the following journals and more: J. Biol. Chemistry, European Journal of Immunology, FEBS, CHEM BIOCHEM, Journal of Cell Biology, Blood, J. of Exp. Medicine, Cell Metabolism

Community Outreach
Speaker at the Goodman cancer centre public evening lecture on prostate cancer.

Internal Committees
I served as reviewer for the VP-Research internal grants.
I serve on the Recruitment committee St-Mary’s chair in breast cancer.
Award committee of the Faculty of Medicine

External Committees
I maintained the following appointments and contributed by conference call as:
Secretary, International Society of Pathophysiology
Member of the Advisory Committee On Research, Canadian Cancer Society
Member of the advisory committee: International Consortium on Mouse Genetics
Member of the “Table de travail sur la recherche”, Montreal In Vivo.

Invited speaker
Phosphatases in diseases. Monash University, Australia 2012
Aichi Cancer Center Research Institute, Nagoya Japan. March 30th, 2012
Tyrosine phosphatases in human diseases, Kobe University Medical School, Japan. June 1, 2012.
The Protein Tyrosine Phosphatases. Meeting Keynote lecturer. Signaling Quebec, Becancour Quebec, Canada. June 14, 2012
University of North Carolina. Dept of cardiology, Dec. 3 2012 PTP1B in cardiovascular and metabolic diseases
Tyrosine phosphatases in the normal and disease brain. Dept of Neurosciences, University of Ottawa November 26, 2012
University of North Carolina. Dept of cardiology, Dec. 3 2012 PTP1B in cardiovascular and metabolic diseases
YAMANAKA, Yojiro

Grant reviews
2011, 2012, Czech Science Foundation (as an external expert)

Journal Reviews
Reproduction (2012-Oct, 2010-Nov, Dec)
PLOS one (2012-Nov)

Meetings organized
Nov.7 2012, 2nd MAD symposium, organizer

Internal Service/Committees
2012 Sep- Interim manager of the GCRC transgenic facility
2011 Jan- 2013 Dec A member of the Postgraduate Awards Committee of the Faculty of Medicine
2010 Apr- Director of the GCC transgenic facility

Invited speaker
2012 Apr. Montreal Children’s Hospital, Canada

YANG, Xiang-Jiao

Journals
Editorial Board Member, Genes & Cancer, 2009-present
Advisory Board Member, Biochem. J., 2010-present
PeerJ (an online journal to be launched by a founder of PLOS One), 07/2012-present

Grant Panels
CIHR Postdoctoral Fellowship Review Committee Member, 2011-present

Internal Committees
Goodman Cancer Center, recruitment committee member, 2007-present
Goodman Cancer Center, Space & equipment committee member, 2012-present
MUHC (McGill University Health Center) Research Institute, 2003-present. Two competitions/year; reviewing ~35 applications per competition (~10 hrs/yr)

Ad hoc grant reviews
NSERC
Israel Science Foundation (ISF)
Research Grants Council, Hong Kong
National Science Council, Taiwan
ZANNIS-HADJOPOULOS, Maria

Editorial Board
1997 Member, Editorial Board, International Society for Gene Therapy & Molecular Biology

Internal Committees
1984-present Member, Royal Victoria Hospital Ethics
1993-present Medical Education Committee, Dept. of Oncology
1999-present Coordinator, Oncology Graduate Program (Stream)
2000-2014 Elected Member (every 2 years), McGill Association of University Teachers MAUT) Council
2004-present Member, McGill Centraide Campaign Committee (MAUT Representative)
2006-present Member, Biochemistry Departmental Tenure Committee
2006-present Member, Biochemistry Department Recruiting Committee
2010-2013 Assessor for McGill University (nominated), Harassment, Sexual Harassment and Discrimination Prohibited by Law

External Committees
1997-present Member, Organizing Committee/Scientific Advisory Board of the Annual Conferences, International Society for Gene Therapy and Molecular Biology
1999-present Member, Scientific Advisory Board, Replicor
2003-present External Reviewer, European Science Foundation/EUROCORES
2004-present Member, Academic Committee, Hellenic Scholarships Foundation
2005-present Evaluator of grant applications submitted to the Greek Ministry of Research and Technology (PENED)
2008-present Member, Hellenic Quality Assurance Agency For Higher Education (H.Q.A.A.), evaluations of Departments in the field of Life Sciences.
2009-present Member, Mispro Biotech Animal Care Committee

Ongoing
Member, Dept. of Biochemistry Hiring Committee
Member, Goodman Cancer Centre Recruiting Committee
Pro-Dean, McGill Graduate and Postdoctoral Studies
Member, Ph.D. Thesis Defense Committees, External and Internal examiner, M.Sc. and Ph.D. Theses

Invited speaker
Department of Pathology and Anatomy, University of Athens, May 25, 2012

ZOGOPOULOS, George

Internal Committees
2013-present Member, Training Committee, Rosalind and Morris Goodman Cancer Research Centre
2012 Reviewer, Studentship and Fellowship Competition, McGill Integrated Cancer Research Training Program
2012 Reviewer, Studentship and Fellowship Competition, the Research Institute of the McGill University Health Centre.
External Committees
2011-present  Member, Research Committee, American Hepato-Pancreato-Biliary Association.

Invited Speaker
Quebec Pancreas Cancer Study, Cancer Axis Research Day, the Research Institute of the McGill University Health Centre, Montreal, Quebec, 2012.
Le Whipple dans l’adénocarcinome du pancreas, 43e congress, L’Association québécoise de chirurgie, Quebec City, Quebec, May 2012.